Astellas' sales up despite generic Prograf challenges
This article was originally published in Scrip
Executive Summary
Generic competition to Prograf (tacrolimus) in the US continued to weigh on Astellas in the fiscal first quarter ended 30 June, although contributions from US acquisition OSI and newer products offset the decline.